Literature DB >> 31173646

The spectrum of mutations predisposing to familial breast cancer in Poland.

Cezary Cybulski1, Wojciech Kluźniak1, Tomasz Huzarski1,2, Dominika Wokołorczyk1, Aniruddh Kashyap1, Bogna Rusak1, Klaudia Stempa1, Jacek Gronwald1, Agata Szymiczek3, Maryam Bagherzadeh3, Anna Jakubowska1,4, Tadeusz Dębniak1, Marcin Lener1, Helena Rudnicka1, Marek Szwiec5, Joanna Jarkiewicz-Tretyn6, Małgorzata Stawicka2, Paweł Domagała7, Steven A Narod3,8, Jan Lubiński1, Mohammad R Akbari3,8.   

Abstract

To optimize genetic testing, it is necessary to establish the spectrum of breast cancer-predisposing mutations in particular ethnic groups. We studied 1,018 women with a strong family history for breast cancer (families with hereditary breast cancer; HBC) from genetically homogenous population of Poland, which is populated by ethnic Slavs, for mutations in 14 cancer susceptibility genes. Additionally, we compared the frequency of candidate pathogenic variants in breast cancer cases and controls. Germline mutations were detected in 512 of 1,018 probands with breast cancer (50.3%), including BRCA1/2 mutations detected in 420 families and non-BRCA mutations seen in 92 families. Thirteen BRCA1/2 founder mutations represented 84% of all BRCA1/2-positive cases. Seven founder mutations of CHEK2, PALB2, NBN and RECQL represented 73% of all non-BRCA-positive cases. Odds ratios for hereditary breast cancer were 87.6 for BRCA1, 15.4 for PALB2, 7.2 for CHEK2, 2.8 for NBN and 15.8 for RECQL. Odds ratios for XRCC2, BLM and BARD1 were below 1.3. In summary, we found that 20 founder mutations in six genes (BRCA1/2, CHEK2, PALB2, NBN and RECQL) are responsible for 82% of Polish hereditary breast cancer families. A simple test for these 20 mutations will facilitate genetic testing for breast cancer susceptibility in Poland. It may also facilitate genetic testing for breast cancer susceptibility in other Slavic populations and women of Slavic descent worldwide.
© 2019 UICC.

Entities:  

Keywords:  ATM; BRCA1; BRCA2; CHEK2; NBN; PALB2; RECQL; breast cancer; hereditary; mutation; sequencing

Mesh:

Year:  2019        PMID: 31173646     DOI: 10.1002/ijc.32492

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Founder vs. non-founder BRCA1/2 pathogenic alleles: the analysis of Belarusian breast and ovarian cancer patients and review of other studies on ethnically homogenous populations.

Authors:  G A Yanus; E L Savonevich; A P Sokolenko; A A Romanko; V I Ni; E Kh Bakaeva; O A Gorustovich; I V Bizin; E N Imyanitov
Journal:  Fam Cancer       Date:  2022-05-21       Impact factor: 2.375

2.  High Number of Familial Breast Cancer Cases in the Arabian Gulf Countries: Investigating the Reasons.

Authors:  Eiman M Mohammed
Journal:  Breast Cancer (Auckl)       Date:  2022-06-28

3.  Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.

Authors:  Renan Gomes; Pricila da Silva Spinola; Ayslan Castro Brant; Bruna Palma Matta; Caroline Macedo Nascimento; Silvia Maria de Aquino Paes; Cibele Rodrigues Bonvicino; Anna Claudia Evangelista Dos Santos; Miguel Angelo Martins Moreira
Journal:  Breast Cancer Res Treat       Date:  2020-10-30       Impact factor: 4.872

4.  PALB2 mutations and prostate cancer risk and survival.

Authors:  Dominika Wokołorczyk; Wojciech Kluźniak; Klaudia Stempa; Bogna Rusak; Tomasz Huzarski; Jacek Gronwald; Katarzyna Gliniewicz; Aniruddh Kashyap; Sylwia Morawska; Tadeusz Dębniak; Anna Jakubowska; Marek Szwiec; Paweł Domagała; Jan Lubiński; Steven A Narod; Mohammad R Akbari; Cezary Cybulski
Journal:  Br J Cancer       Date:  2021-05-18       Impact factor: 7.640

5.  Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer.

Authors:  Wojciech Kluźniak; Dominika Wokołorczyk; Bogna Rusak; Tomasz Huzarski; Aniruddh Kashyap; Klaudia Stempa; Helena Rudnicka; Anna Jakubowska; Marek Szwiec; Sylwia Morawska; Katarzyna Gliniewicz; Karina Mordak; Małgorzata Stawicka; Joanna Jarkiewicz-Tretyn; Magdalena Cechowska; Paweł Domagała; Tadeusz Dębniak; Marcin Lener; Jacek Gronwald; Jan Lubiński; Steven A Narod; Mohammad R Akbari; Cezary Cybulski
Journal:  Cancers (Basel)       Date:  2019-10-13       Impact factor: 6.639

6.  Inherited variants in XRCC2 and the risk of breast cancer.

Authors:  Wojciech Kluźniak; Dominika Wokołorczyk; Bogna Rusak; Tomasz Huzarski; Jacek Gronwald; Klaudia Stempa; Helena Rudnicka; Aniruddh Kashyap; Tadeusz Dębniak; Anna Jakubowska; Marcin Lener; Marek Szwiec; Joanna Tomiczek-Szwiec; Joanna Jarkiewicz-Tretyn; Magdalena Cechowska; Paweł Domagała; Agata Szymiczek; Maryam Bagherzadeh; Jan Lubiński; Steven A Narod; Mohammad R Akbari; Cezary Cybulski
Journal:  Breast Cancer Res Treat       Date:  2019-08-28       Impact factor: 4.872

Review 7.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.

Authors:  Lenka Stolarova; Petra Kleiblova; Marketa Janatova; Jana Soukupova; Petra Zemankova; Libor Macurek; Zdenek Kleibl
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

8.  Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations.

Authors:  Malwina Suszynska; Piotr Kozlowski
Journal:  Genes (Basel)       Date:  2020-07-15       Impact factor: 4.096

Review 9.  The Many Faces of Gene Regulation in Cancer: A Computational Oncogenomics Outlook.

Authors:  Enrique Hernández-Lemus; Helena Reyes-Gopar; Jesús Espinal-Enríquez; Soledad Ochoa
Journal:  Genes (Basel)       Date:  2019-10-30       Impact factor: 4.096

10.  Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?

Authors:  Tu Nguyen-Dumont; Pawel Karpinski; Maria M Sasiadek; Hayane Akopyan; Jason A Steen; Derrick Theys; Fleur Hammet; Helen Tsimiklis; Daniel J Park; Bernard J Pope; Ryszard Slezak; Agnieszka Stembalska; Karolina Pesz; Nataliya Kitsera; Aleksandra Siekierzynska; Melissa C Southey; Aleksander Myszka
Journal:  Genet Res (Camb)       Date:  2020-08-10       Impact factor: 1.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.